Conceptualising access in the direct-acting antiviral era: An integrated framework to inform research and practice in HCV care for people who inject drugs

被引:34
|
作者
Hoj, Stine Bordier [1 ]
Jacka, Brendan [1 ]
Minoyan, Nanor [1 ,2 ]
Artenie, Andreea Adelina [1 ,2 ]
Bruneau, Julie [1 ,3 ]
机构
[1] CRCHUM, 900 Rue St Denis,Local R05-746, Montreal, PQ H2X 0A9, Canada
[2] Univ Montreal, Ecole Sante Publ, 7101 Ave Parc, Montreal, PQ H3N 1X9, Canada
[3] Univ Montreal, Fac Med, Dept Med Familiale & Med Urgence, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada
基金
加拿大健康研究院;
关键词
Hepatitis C virus; Treatment; Health services; Injection drug use; Theoretical framework; Ecological framework; HEPATITIS-C VIRUS; PATIENT-REPORTED OUTCOMES; LONG-TERM CONDITIONS; HEALTH-CARE; HIV CARE; UNDERSTANDING BARRIERS; TREATMENT CANDIDACY; BEHAVIORAL-MODEL; UNITED-STATES; SPECIALIST ASSESSMENT;
D O I
10.1016/j.drugpo.2019.04.001
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
As direct-acting antiviral (DAA) therapy costs fall and eligibility criteria are relaxed, people who inject drugs (PWID) will increasingly become eligible for HCV treatment. Yet eligibility does not necessarily equate to access. Amidst efforts to expand treatment uptake in this population, we seek to synthesise and clarify the conceptual underpinnings of access to health care for PWID, with a view to informing research and practice. Integrating dominant frameworks of health service utilisation, care seeking processes, and ecological perspectives on health promotion, we present a comprehensive theoretical framework to understand, investigate and intervene upon barriers and facilitators to HCV care for PWID. Built upon the concept of Candidacy, the framework describes access to care as a continually negotiated product of the alignment between individuals, health professionals, and health systems. Individuals must identify themselves as candidates for services and then work to stake this claim; health professionals serve as gatekeepers, adjudicating asserted candidacies within the context of localised operating conditions; and repeated interactions build experiential knowledge and patient-practitioner relationships, influencing identification and assertion of candidacy over time. These processes occur within a complex social ecology of interdependent individual, service, system, and policy factors, on which other established theories provide guidance. There is a pressing need for a deliberate and nuanced theory of health care access to complement efforts to document the HCV 'cascade of care' among PWID. We offer this framework as an organising device for observational research, intervention, and implementation science to expand access to HCV care in this vulnerable population. Using practical examples from the HCV literature, we demonstrate its utility for specifying research questions and intervention targets across multiple levels of influence; describing and testing plausible effect mechanisms; and identifying potential threats to validity or barrierS to research translation.
引用
收藏
页码:11 / 23
页数:13
相关论文
共 50 条
  • [21] Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review
    Moaz Abdelwadoud
    T. Joseph Mattingly
    Hemanuel Arroyo Seguí
    Emily F. Gorman
    Eleanor M. Perfetto
    The Patient - Patient-Centered Outcomes Research, 2021, 14 : 471 - 484
  • [22] Clinicians'Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs
    Asher, Alice K.
    Portillo, Carmen J.
    Cooper, Bruce A.
    Dawson-Rose, Carol
    Vlahov, David
    Page, Kimberly A.
    SUBSTANCE USE & MISUSE, 2016, 51 (09) : 1218 - 1223
  • [23] Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review
    Abdelwadoud, Moaz
    Mattingly, T. Joseph, II
    Segui, Hemanuel Arroyo
    Gorman, Emily F.
    Perfetto, Eleanor M.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (05): : 471 - 484
  • [24] Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting
    Socias, M. Eugenia
    Ti, Lianping
    Wood, Evan
    Nosova, Ekaterina
    Hull, Mark
    Hayashi, Kanna
    Debeck, Kora
    Milloy, M-J
    LIVER INTERNATIONAL, 2019, 39 (08) : 1400 - 1407
  • [25] Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs
    Williams, Beth E.
    Nelons, Devynne
    Seaman, Andrew
    Witkowska, Martyna
    Ronan, Wren
    Wheelock, Haven
    Zaman, Atif
    Garcia, Jonathan
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2019, 72 : 138 - 145
  • [26] Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era
    Gahrton, Caroline
    Naver, Georg
    Warnqvist, Anna
    Dalgard, Olav
    Aleman, Soo
    Kaberg, Martin
    INTERNATIONAL JOURNAL OF DRUG POLICY, 2024, 128
  • [27] Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    Lima, Viviane D.
    Rozada, Ignacio
    Grebely, Jason
    Hull, Mark
    Lourenco, Lillian
    Nosyk, Bohdan
    Krajden, Mel
    Yoshida, Eric
    Wood, Evan
    Montaner, Julio S. G.
    PLOS ONE, 2015, 10 (12):
  • [28] Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs
    Cunningham, Evan B.
    Hajarizadeh, Behzad
    Amin, Janaki
    Hellard, Margaret
    Bruneau, Julie
    Feld, Jordan J.
    Cooper, Curtis
    Powis, Jeff
    Litwin, Alain H.
    Marks, Philippa
    Dalgard, Olav
    Conway, Brian
    Moriggia, Alberto
    Stedman, Catherine
    Read, Phillip
    Bruggmann, Philip
    Lacombe, Karine
    Dunlop, Adrian
    Applegate, Tanya L.
    Matthews, Gail, V
    Fraser, Chris
    Dore, Gregory J.
    Grebely, Jason
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (08) : 1392 - 1400
  • [29] Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis
    Hajarizadeh, Behzad
    Cunningham, Evan B.
    Reid, Hannah
    Law, Matthew
    Dore, Gregory J.
    Grebely, Jason
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (11): : 754 - 767
  • [30] Low Hepatitis C Reinfection Following Direct-acting Antiviral Therapy Among People Who Inject Drugs on Opioid Agonist Therapy
    Akiyama, Matthew J.
    Lipsey, Daniel
    Heo, Moonseong
    Agyemang, Linda
    Norton, Brianna L.
    Hidalgo, Jennifer
    Lora, Kiara
    Litwin, Alain H.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (12) : 2695 - 2702